![SDS-PAGE for CoV-S[679-833] Recombinant proteins](https://www.proteogenix.science/wp-content/uploads/documents/validation/sds-validation-cov-s679-833.png)
![SDS-PAGE for CoV-S [819-919] Recombinant proteins](https://www.proteogenix.science/wp-content/uploads/documents/validation/sds-validation-cov-s-819-919.png)
Cart (0 Items)
Your cart is currently empty.
View Products
Brand: ProteoGenix
Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
- Isotype:
- IgG
€200.00
100ug 0% OFF + 200 loyalty points- In Stock
- Free shipping in EU on orders > €500
- Wide range of unique reagents
- Fast worldwide delivery
Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade
SDS-PAGE for Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb
Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb binds to RBD Domain in Indirect ELISA Assay
Immobilized RBD Domain (cat. No.PX-COV-P046) at 0.5µg/mL (100µL/well) can bind to Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb (cat. No.PX-TA1637) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
- Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3,Hang Ma, Chien-Te K. Tseng, Huifang Zong, Yunji Liao, et al., bioRxiv 2022.02.25.482049; doi: https://doi.org/10.1101/2022.02.25.482049
- Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike, Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijalkowska, Simon Devos, Anne-Sophie Desmet, Jackeline Cecilia Zavala Marchan, Toon Venneman, Koen Sedeyn, Marlies Ballegeer, Manon Vanheerswynghels, Caroline De Wolf, Hans Demol, Pieter Vanhaverbeke, Gholamreza Hassanzadeh Ghassabeh, Chiara Lonigro, Viki Bockstal, Manuela Rinaldi, Rana Abdelnabi, Johan Neyts, Susan Marqusee, Bart N. Lambrecht, Nico Callewaert, Han Remaut, Xavier Saelens, Bert Schepens, bioRxiv 2023.03.10.531533; doi: https://doi.org/10.1101/2023.03.10.531533
- Fiedler, S., Devenish, S.R.A., Morgunov, A.S. et al. Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. Sci Rep 12, 19791 (2022). https://doi.org/10.1038/s41598-022-22214-z
- Fiaschi, L.; Biba, C.; Varasi, I.; Bartolini, N.; Paletti, C.; Giammarino, F.; Saladini, F.; Zazzi, M.; Vicenti, I. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. Viruses 2024, 16, 168. https://doi.org/10.3390/v16020168
- De Cae, S., Van Molle, I., van Schie, L. et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base. Nat Commun 16, 5040 (2025). https://doi.org/10.1038/s41467-025-60250-1
Add a review
Toshi — October 3, 2021
★★★☆☆
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody did not show weak inhibition of all variants tested (IC50 344.03 ng/mL for Delta, >500 ng/mL for Gamma and Alpha, 244.1 ng/mL for the wild type).